FluMist is an efficacious and safely tolerated intranasal influenza vaccine. FluMist has gained approval from the FDA for self-administration by...

A phase 3 trial showed Kerendia reduced the risk of cardiovascular death by 16% compared to placebo. Hyperkalemia was greater...

Epkinly showed an overall response rate of 82% with 62.5% of patients achieving complete response. 65% of patients had grade...

Afami-cel (Tecelra) is the first genetically engineered T-cell receptor therapy for synovial sarcoma Afami-cel demonstrated an overall response rate of...

Relutrigine resulted in a 46% reduction in seizures and seizure freedom in 30% of patients. Patients also experienced meaningful improvements...

Treatment with BNT111 + cemiplimab showed a statistically significant overall response in patients with inoperable or advanced-stage anti-PD-1 refractory melanoma...

Giroctocogene fitelparvovec, a novel gene therapy, demonstrated superiority to routine therapy in treating hemophilia A. Giroctocogene fitelparvovec resulted in a...

ETH47, a nasally administered mRNA drug candidate was safe,well-tolerated by healthy participants, and did not result in any clinically relevant...

Mezagitamab achieved a sustained platelet response and symptomatic relief in patients treated for chronic ITP. Mezagitamab showed a favorable safety...

ANX005 led to significant reductions in GBS-associated disability, improved muscle power, reduced nerve damage, and a reduced need for mechanical...